11:30 am–12:30 pm Saturday, September 7

Beyond the Cure: The Children’s Oncology Group Uses Evidence and Clinical Trials to Study Late Effects in Childhood Cancer Survivors (C229)

coglogoChildhood cancer survivors are living longer than ever before, with overall survival rates exceeding 80%. As a result, survivors are living with chronic late health effects related to their curative treatments. Late effects may include second malignancies, endocrinopathies, cardiomyopathy, infertility, pulmonary function deficits, renal/ocular/auditory disorders, neurocognitive deficits, and metabolic syndrome.

Read more...
Speaker:
Eleanor Hendershot, MN BScN RN(EC)
CNE Hours
1
RX Hours
0.17
2:15–3:15 pm Saturday, September 7

A New Tool for Documenting the Child's Report of Cancer Treatment Toxicity (230)

The National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE) is the standard lexicon for grading adverse events (AEs) in oncology trials. Children with cancer experience significant numbers of subjective AEs such as fatigue, pain, or sadness. The current standard is that AEs are reported only by clinicians, even though 30% of the 790 CTCAE items are subjective.

Read more...
11:30 am–12:30 pm Saturday, September 7

Creating the Spark - Inspire Learning with Interactive Activities for the Chemotherapy/Biotherapy Provider Course (226)

The 4th edition of the APHON Chemotherapy and Biotherapy Curriculum was published earlier this year. Extensive updates to the 4th edition book and live instructor course created a need to provide ongoing support for the 550 instructors as they familiarize themselves with the updated content and revised lectures. Central to the updated material is a focus on interactive teaching strategies.

Read more...
4:15–5:15 pm Friday, September 6

Immune-Mediated Thrombocytopenia: An Overview (221)

Immune-mediated thrombocytopenia, or “ITP,” is one of the most common causes of symptomatic thrombocytopenia in children and adolescents. Clinical presentation and course, epidemiology, diagnostic modalities and criteria, treatment options, and long-term sequelae will be reviewed with attention to the nurse/advanced practice nurse who desires a comprehensive overview of the subject. Case studies will be utilized to highlight the frequent clinical variance of the condition. Read more...
4:15–5:15 pm Friday, September 6

CLABSIs in Pediatric Hem/Onc/BMT Patients – Why Aren’t We at Zero, and Will We Ever Get There? (220)

Central line-associated bloodstream infections (CLABSIs) continue to be an important source of morbidity for children with cancer and those undergoing hematopoietic stem cell transplant. As many institutions strive to achieve rates of zero, nurses need to be aware of distinct challenges involving the pediatric hematology/oncology/transplant population.

Read more...
Speaker:
Lauri Linder, PhD APRN CPON®
CNE Hours
1
11:30 am–12:30 pm Friday, September 6

Foundations of Pediatric Neuro-Oncology (214)

Pediatric central nervous system (CNS) tumors are a diverse group of tumors that together represent the most common solid tumor in children, with approximately 4,300 new cases diagnosed in the US each year. Management of children with CNS tumors requires knowledge of the unique aspects of care associated with this particular patient population beyond general oncology care.

Read more...
Speaker:
Cheryl Fischer, MSN RN CPNP
CNE Hours
1
11:30 am–12:30 pm Friday, September 6

The Forgotten Organ- Nephrotoxicity and other Kidney Disorders in Childhood Cancer (213)

Development of kidney disease is a significant occurrence among children and adolescent patients treated for cancer and require prompt attention, intervention, and follow-up. Renal disease in the pediatric cancer setting is often an underdiagnosed condition, partly due to the emphasis and priority of achieving a cure. Renal disease in the young patient with cancer may result from the malignant process itself or from adverse effects from treatment, including chemotherapy, radiation therapy, surgery, or supportive therapy.

Read more...
5:00–6:00 pm Thursday, September 5

Non-Pharmacologic Treatment of Pain in Sickle Cell Disease (207)

Sickle cell disease (SCD) is characterized by episodes of severe and unpredictable pain that requires adaptation to remain healthy and functional. A more holistic view of pain assessment and treatment is necessary to address the bio-psychosocial needs of the individual in or at risk for pain. The treatment of SCD should include all available modalities to enhance the disease process, pain management, and psychosocial functioning.

Read more...
Speaker:
Megan Coco, MSN RN CPNP-PC
CNE Hours
1
5:00–6:00 pm Thursday, September 5

Symptom Assessment and Associated Biomarkers (206)

Altered sleep and increased fatigue are reported as two of the most distressing symptoms during treatment and into survivorship. Prevalence of disrupted sleep and fatigue have been reported to be higher among patients treated for CNS tumors, those treated with radiation therapy, solid tumors, and Hodgkin Lymphoma; however, changes in sleep and fatigue have been reported across all cancer diagnoses. To elucidate the biological mechanism underlying these symptoms, symptom science has evolved from descriptive studies of symptom occurrence to the measurement of biological processes.

Read more...
3:45–4:45 pm Thursday, September 5

Self-reported Symptom Experiences and Self-management Strategies used by Children, Adolescents and Young Adults with Cancer: What Can We Learn? (201)

Obtaining relief from symptoms of disease and treatment is essential to the quality of life of children, adolescents, and young adults (AYAs) receiving treatment for cancer. With person-centered care, clinicians must understand the individual symptom experience of every child and AYA and promote optimal symptom management. Mobile technology-based resources, such as apps, are emerging as novel ways to support symptom reporting by patients during and between clinical encounters and to teach symptom self-management skills.

Read more...
Subscribe to this RSS feed